Bli medlem
Bli medlem

Du är här

2016-11-01

Oasmia Pharmaceutical Announces Change in Ownership

harmaceutical Announces Change in Ownership

Uppsala, Sweden, 2016-11-01 21:10 CET (GLOBE NEWSWIRE) --

Uppsala, Sweden, November 1, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a
developer of a new generation of drugs within human and veterinary oncology
announced today that Nexttobe AB has divested its shareholder position in
Oasmia in its entirety to a consortium of professional Swedish and
international investors.

Notes to editors:

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new
generations of drugs in the field of human and veterinary oncology. The
company’s product development aims to create and manufacture novel nanoparticle
formulations and drug-delivery systems based on well-established cytostatics
which, in comparison with current alternatives, show improved properties,
reduced side-effects, and expanded applications. The company’s product
development is based on its proprietary in-house research and company patents.
Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange
(OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Julian Aleksov
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.